Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Sleep Trackers & Wearables

Sleep Trackers & Wearables · Measurement

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

0 human trials, about 60 studies, >800 participants in pooled validation meta-analyses; individual studies 30-100. The written rationale for this grade is still being prepared.

FDA
General sleep tracking is wellness, un-cleared. Specific features cleared: Apple Watch ECG/AFib (510k) and sleep apnea notification (cleared Sept 2024, US); Samsung sleep apnea (De Novo, 2024, US). Sleep-stage output is not FDA cleared.
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

These are wellness devices, not diagnostic tools. Sleep-stage breakdowns are inferred and should not be read as clinically accurate, and devices over-call or under-call wake periods inconsistently (low wake specificity, roughly 29 to 52% in a 2025 six-device study). A documented harm is orthosomnia: a perfectionist preoccupation with achieving ideal tracker numbers that is itself associated with worse sleep, described by Baron and colleagues in a 2017 Journal of Clinical Sleep Medicine case series and now measurable with the 2025 Bergen Orthosomnia Scale, which correlates with sleep effort, health anxiety and perfectionism. Users may extend time in bed chasing higher scores, which can reinforce insomnia. The American Academy of Sleep Medicine (2018 position statement, 2021 update) states consumer sleep technology should not replace validated diagnostic testing and cannot diagnose sleep disorders. Suspected sleep apnea, chronic insomnia, persistent sleep-related anxiety, or other clinical sleep concerns require evaluation by a qualified provider or accredited sleep clinic, not interpretation of app data. Smartwatch sleep-apnea notification features (Apple, Samsung) are screening alerts, not diagnoses, and a positive alert still requires clinical confirmation by a qualified provider.

Consumer sleep wearables (Oura Ring, Whoop, Apple Watch, Fitbit/Google, Garmin, Samsung Galaxy Watch, and bed-based systems like Eight Sleep) estimate sleep from sensors that record body movement (accelerometry), heart rate and heart rate variability (photoplethysmography), skin temperature, and in some cases blood oxygen. None of these signals is the electroencephalogram (EEG) that defines sleep stages under clinical scoring standards (Rechtschaffen and Kales 1968, updated by the American Academy of Sleep Medicine in 2007). Stage outputs (light, deep, REM) are algorithmic inferences, not direct measurements. The validation literature is consistent on a split verdict: against in-lab polysomnography (PSG) these devices estimate total sleep time and discriminate sleep from wake reasonably well in healthy adults, but four-stage classification is weaker and the strongest accuracy figures come from manufacturer-funded studies. A 2025 Journal of Clinical Sleep Medicine meta-analysis of 24 studies and 798 participants found wrist-worn devices underestimated total sleep time by about 17 minutes on average and did not even evaluate staging. A 2025 SLEEP Advances head-to-head of six devices reported only fair-to-moderate staging agreement with PSG (Cohen's kappa roughly 0.21 to 0.53), with high sensitivity to sleep but low specificity for detecting wake. For circadian work the genuine value is not the sleep-stage pie chart; it is the longitudinal, every-night record of timing, sleep regularity, resting heart rate, HRV trend, and skin-temperature rhythm, which can surface patterns associated with social jetlag, shifting bedtimes, or temperature changes across a menstrual cycle.

These devices measure movement, heart rate, HRV and temperature. They infer sleep stages.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Tracking sleep timing and night-to-night regularity (a circadian signal)
  • Estimating total sleep time and bedtime drift over weeks (with a known underestimate bias)
  • Trending resting heart rate and HRV as recovery proxies
  • Detecting relative skin-temperature rhythm shifts (e.g. across a menstrual cycle)
  • Behavior-change nudges toward consistent sleep and wake times
  • Population and field research where in-lab PSG is impractical

What people get wrong

  • Often saidMy tracker tells me exactly how much deep sleep and REM I got.

    ActuallyStages are inferred from movement, heart rate, HRV and temperature, not measured from brain activity. A 2025 head-to-head of six devices (SLEEP Advances) found only fair-to-moderate agreement with polysomnography for four-stage classification (Cohen's kappa about 0.21 to 0.53). The total-sleep-time and sleep-versus-wake numbers are more trustworthy than the stage breakdown, and even those carry a systematic bias: a 2025 JCSM meta-analysis found wrist devices underestimate total sleep time by about 17 minutes.

  • Often saidA bad sleep score means I slept badly and need to fix it.

    ActuallyA single night's score is a noisy estimate, and fixating on it is associated with orthosomnia, where preoccupation with the data is associated with worse sleep (Baron et al. 2017 case series; a validated Bergen Orthosomnia Scale was published in 2025). Trends over weeks (timing, regularity) are more meaningful than any one night's number, and a qualified provider should evaluate persistent sleep concerns rather than a tracker app.

  • Often saidThese devices can tell me if I have a sleep disorder.

    ActuallyThey cannot diagnose. The AASM (2018 position statement, 2021 update) states consumer sleep technology should not replace validated diagnostic testing. Even FDA-cleared apnea-notification features (Apple, Samsung, 2024) are screening alerts that require clinical confirmation.

  • Often saidThe brand's own study proves my device is accurate.

    ActuallyManufacturer-funded validations report the highest accuracy figures: Oura's Gen3 study reports 91.7 to 91.8% overall accuracy, but all senior authors disclose Oura Health Oy funding. Independent multi-device studies report lower stage agreement. A brand figure establishes what the maker asserts, not that the claim is independently confirmed.

Who profits, and who pushes back

  • Dr. Kelly Glazer Baron

    Pushes backBehavioral sleep-medicine researcher, University of Utah; lead author of the orthosomnia case series (JCSM 2017) and co-author of the Bergen Orthosomnia Scale (2025)

    I would never initiate treatment based on somebody's data from their device. Treatment for insomnia is based on people's subjective experience of their sleep.

  • Dr. Michael Grandner

    Pushes backDirector, Sleep and Health Research Program, University of Arizona

    The 'score,' the 'recovery' are mostly nonsense. It's horoscopes.

  • American Academy of Sleep Medicine

    Pushes backProfessional sleep-medicine society (position statement 2018, update 2021)

    Patient-generated health data should be considered in the context of a comprehensive sleep evaluation and should not replace validated diagnostic testing.

  • Oura (brand)

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itManufacturer

    Sells the device and publishes its own PSG validation claims (e.g. 79% four-stage agreement, Sensors 2021). Commercial interest; brand claims establish what Oura asserts, not that the claim is independently confirmed.

  • Whoop (brand)

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itManufacturer

    Subscription wearable; cites third-party PSG validation. Commercial interest in accuracy framing.

  • Athlete brand ambassadors

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itPaid endorsers

    PAID: formal brand-ambassador and sponsorship deals (e.g. Whoop with LeBron James, Michael Phelps, Steven Bartlett; Oura partnered with Olympic athletes and named Official Wearable of Team USA/LA28). Endorsements are incentivized, not independent assessments of accuracy.

  • Biohacking / wellness influencers with Oura or Whoop affiliate codes

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itAffiliate creators

    PAID: Oura and Whoop run affiliate/partner programs paying commission on referrals; many such creators also receive free devices. Discount-code promotion is monetized.

  • Eight Sleep (brand)

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itManufacturer

    Sells temperature-regulating mattress cover with sleep tracking; publishes its own performance figures. Commercial interest.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
USA42%
Europe27%
Asia-Pacific23%
Other8%

Research published from: Global.

How we got here

Measuring sleep without a lab traces to research actigraphy. In the early 1970s, Kupfer, Foster and colleagues used telemetric movement data to estimate sleep timing in psychiatric patients. In 1978, Daniel Kripke and colleagues reported strong agreement between wrist-actigraphy and PSG sleep-duration measures in healthy subjects. In 1982, Webster published the first automated algorithm to score wrist-actigraph data; its rescoring rules were refined in 1992 into the widely used Cole-Kripke algorithm (Sleep, vol. 15, pp. 461-469). The clinical reference standard these methods were validated against, polysomnography, was standardized by Allan Rechtschaffen and Anthony Kales in their 1968 scoring manual, updated by the AASM in 2007 into the N1/N2/N3/R framework. PSG remains the standard because it records EEG, the only signal that directly defines sleep stages. The consumer era began in the 2010s as accelerometers, optical heart-rate sensors and machine learning moved from research actigraphs into wrist and finger wearables. Oura was founded in Oulu, Finland in 2013 (first ring 2015); Eight Sleep in San Francisco in 2014; Fitbit, Garmin, Apple and Whoop added or expanded sleep features through the decade. The measurement-science lineage is largely a recent Western academic and commercial development, centered in the US and Northern Europe, with major independent validation now global, including work from Asia-Pacific institutions (e.g. University of Tokyo) and European centers (e.g. Antwerp University Hospital).

  1. 1968Rechtschaffen and Kales publish standardized PSG sleep-scoring manual
  2. 1972Early telemetric movement studies estimate sleep timing (Kupfer, Foster et al.)
  3. 1978Kripke et al. validate wrist-actigraphy sleep duration against PSG
  4. 1982Webster publishes first automated actigraphy scoring algorithm
  5. 1992Cole-Kripke algorithm refines automated actigraphy scoring (Sleep 15:461-469)
  6. 2007AASM updates sleep-stage scoring rules (N1/N2/N3/R)
  7. 2013Oura Health founded in Oulu, Finland
  8. 2017Baron et al. describe orthosomnia in JCSM
  9. 2018AASM position statement: consumer sleep technology should not replace validated diagnostic testing
  10. 2020Miller et al. publish independent Whoop-vs-PSG validation
  11. 2021AASM publishes update on evaluating consumer and clinical sleep technologies
  12. 2024FDA clears Apple Watch sleep-apnea notification (510(k) K240929, Sept 13) and authorizes Samsung Galaxy Watch sleep apnea (De Novo, announced Feb 9), US; Oura publishes Gen3 OSSA 2.0 validation (Svensson et al., Sleep Medicine)
  13. 2025Lee et al. JCSM meta-analysis (24 studies, 798 participants) and Antwerp SLEEP Advances six-device head-to-head quantify PSG agreement; Bergen Orthosomnia Scale published (Guldbrandsen, Baron et al.)

At a glance

Directly measured
Movement, heart rate, HRV, skin temperature, SpO2
Inferred (not measured)
Sleep stages (light/deep/REM)
Best validated output
Total sleep time and sleep/wake (good)
Weakest output
4-stage classification (mixed vs PSG)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Sleep Trackers & Wearables. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources